Immune checkpoint inhibitors (ICIs) are effective in classical Hodgkin lymphoma (cHL), but immune-related adverse events (irAEs) may lead to treatment interruption in some patients. We conducted a retrospective cohort study of 145 patients with cHL treated with ICIs between 2015 and 2024. Cohort 1 included 130 patients...
Follicular lymphoma (FL) has traditionally been considered an incurable malignancy characterized by repeated relapses. However, emerging long-term data are increasingly challenging this paradigm. With rituximab, median overall survival approaches 20 years, and only 35-40% of patients require more than one treatment lin...
L. Magnano, A. López-Guillermo, Matthew J. Maurer· Blood· 0 citations
Histologic transformation (HT) is the leading of death in follicular lymphoma (FL), yet outcomes remain poorly defined due to small cohorts and heterogenous definitions. To characterize outcomes and treatment patterns in the rituximab era we analyzed 344 patients with an initial biopsy-confirmed FL diagnosis between 20...
J. Day, M. Larson, C. Casulo et al.· Haematologica· 0 citations
This White Paper written by the Global Lymphoma Registry Alliance (LyRA) discusses the importance and value of lymphoma registries for different stakeholders as well as benefits of forming a global alliance of the registry network.
Eliza A. Hawkes, E. Chung, M. Bishton et al.· Haematologica· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
